In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reata's $450 Million Up-Front Haul Sets A Record But Remains An Outlier

Executive Summary

In late September, Reata Pharmaceuticals Inc. dealt its Phase IIb chronic kidney disease candidate bardoxolone to Abbott Laboratories Inc., and the $450 million down payment easily dwarfs those on other deals around development-stage drug candidates, going back as far as the eye can see.

Related Content

Kidney Disease: A Price-Sensitive Market But A Bundle Of Opportunity
Biotech’s Declaration Of Independence And What Pharma Needs To Do About It
IND Over POC: The New Sweet Spot For Biopharma Dealmaking
IND Over POC: The New Sweet Spot For Biopharma Dealmaking
Investing A La Carte: Making Separate Bets on Discovery and Development to Boost Near-Term Returns
A Look Back At 2010: In Search Of New Biopharma Models
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2010
Pharma: Serious About Change?
Pharma: Serious About Change?
Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts